Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 14, 145-148, February 1, 1954]
© 1954 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eriksen, N.
Right arrow Articles by Lippincott, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eriksen, N.
Right arrow Articles by Lippincott, S. W.

The Precipitation of Serum Proteins by Acidified Sodium Orthovanadate in Neoplastic and Other Diseases*

Nils Eriksen, Lester D. Ellerbrook and Stuart W. Lippincott

( Department of Pathology, School of Medicine, University of Washington, Seattle 5, Wash.)

A modification of Bendien's reaction between acidified sodium orthovanadate and serum has been applied to a series of 462 serum specimens, including 110 normal controls. Of six reagent mixtures of different compositions, one was found to be more sensitive than the others for the detection of abnormal sera. On the basis of an arbitrary dividing point, allowing 5 per cent falsepositive test results among the normal controls, this reagent mixture gave positive test results as follows: 86 per cent in 76 patients with malignant neoplasms but no known metastases; 96 per cent in 68 patients with malignant neoplasms and known metastases; 62 per cent in 58 patients with benign neoplasms; 67 per cent in 150 patients with miscellaneous non-neoplastic diseases. The low order of specificity speaks against use of the test for diagnostic purposes.

* This work was supported by the Cancer Control Branch (now called Field Investigations and Demonstrations Branch), National Cancer Institute, United States Public Health Service.

Received 10/16/53.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1954 by the American Association for Cancer Research.